Phanes Therapeutics’ anti-claudin 18.2 antibody patent granted in the US

SAN DIEGO, Jan. 17, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent (Patent No. US 11,555,070)…

Click here to view original post